|Articles|March 1, 2012
- Pharmaceutical Executive-03-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - March 2012
Leading in Emerging Markets
Advertisement
Articles in this issue
over 13 years ago
Novartis: LEADing in Emerging Marketsover 13 years ago
How Can We Fix the FDA?over 13 years ago
The Italian's Jobover 13 years ago
Off the Hook? Pharm Exec's Annual Press Auditover 13 years ago
The Maestrosover 13 years ago
The (Life) Science of Digital Connectionsover 13 years ago
Judging a Pill by its Coverover 13 years ago
When Talk is Not So CheapNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences
3
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
4
Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age
5
